Sunshine Heart rises after presenting data on C-Pulse system Shares of medical device maker Sunshine Heart (SSH) have risen throughout the session after the company presented follow-up data from six patients implanted with its C-Pulse Heart Assist System as part of a FDA approved feasibility study. In slides made available on the company's website, Sunshine Heart stated that three of the six patients showed clinically significant improvement allowing for discontinuation of device support with explantation of the percutaneous lead. Additionally, Sunshine Heart's hosted its annual analyst and investor breakfast this morning at 7 am. In afternoon trading, shares of Sunshine Heart are up 9% to $6.36. Reference Link
Edwards Lifesciences price target raised to $114 from $103 at Canaccord Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.
Sunshine Heart to present data from six patients implanted with C-Pulse system Sunshine Heart announced that follow-up data from six patients implanted with the C-Pulse Heart Assist System at St. Luke's Hospital – Mid America Heart Institute, as part of a FDA approved, North American Feasibility Study, will be presented later today by Dr. Sanjeev Aggarwal, Director of Mechanical Circulatory Support at Saint Luke's Mid America Heart Institute. Prior to his clinical presentation at the TCT Conference, Dr. Aggarwal will present on a few of these patients who demonstrated clinical signs of myocardial recovery to the investment community at Sunshine Heart's fourth annual analyst and investor breakfast that begins at 7:00am today at the Grand Hyatt Washington.